{Reference Type}: Journal Article
{Title}: The role of stereotactic body radiotherapy in hepatocellular carcinoma: guidelines and evidences.
{Author}: Hu Y;Zhao C;Ji R;Chen W;Shen Q;Chiang CL;Chan J;Ma L;Yang H;Wong T;Ellsworth S;Lo CM;Dawson LA;Kong FS;
{Journal}: J Natl Cancer Cent
{Volume}: 2
{Issue}: 3
{Year}: 2022 Sep
暂无{DOI}: 10.1016/j.jncc.2022.05.002
{Abstract}: Hepatocellular carcinoma (HCC) is a common malignancy with high mortality rates. While surgery can be curative in early-stage disease, 80% of patients cannot undergo surgical resection. Stereotactic body radiotherapy (SBRT), an emerging, non-invasive, precision treatment, has shown promising results across various stages of HCC and has thus been adopted in practice to varying degrees around the world. This article aims to review current guideline recommendations on SBRT, clinical evidence, and outcome comparisons with other local treatment modalities. Attempts are also made to compare the differences in clinical trials between Asian and Western countries.